InspireMD Announces Publication Of 12-Month Results Of CGuard™ EPS SIBERIA Trial In Journals Of The American College of Cardiology: Cardiovascular Interventions
Portfolio Pulse from Benzinga Newsdesk
InspireMD has announced the publication of 12-month results from the CGuard™ EPS SIBERIA trial in the Journals of the American College of Cardiology: Cardiovascular Interventions. This publication could influence the perception of InspireMD's product efficacy.
November 03, 2021 | 9:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
InspireMD's publication of the CGuard™ EPS SIBERIA trial results in a reputable cardiology journal may enhance the perceived efficacy of its product, potentially boosting investor confidence.
The publication in a reputable journal suggests positive trial results, which could enhance the credibility and marketability of InspireMD's CGuard™ EPS. This may lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90